Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
37 hedge funds and large institutions have $41.2M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 11 closing their positions.
112% more capital invested
Capital invested by funds: $19.4M → $41.2M (+$21.8M)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
16% more funds holding
Funds holding: 32 → 37 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$6.5M |
| 2 |
Morgan Stanley
New York
|
+$2.92M |
| 3 |
NYLIM
New York Life Investment Management
New York
|
+$949K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$940K |
| 5 |
RA
Ramius Advisors
New York
|
+$848K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.26M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.64M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.36M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.05M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$507K |
OPNT Hedge Fund Activity: Q4 2022 in Review
37 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2022, worth a combined $41.2M — up 112% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OPNT positions and 11 closed out — a net gain of 6 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was Western Standard LLC, opening a new position worth an estimated $6.5M. The largest seller was HealthInvest Partners, exiting entirely with an estimated $2.26M sold.
- 37 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2022, up from 32 in Q3 2022.
- Funds reported $41.2M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2022, up 112% quarter-over-quarter.
- 17 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 11 closed out, a net change of +6 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Western Standard LLC, an estimated $6.5M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was HealthInvest Partners, an estimated $2.26M sold.
Based on aggregated 13F filings for Q4 2022.